China’s New Drug Regs Overlook Key Issues of Concern to Multinationals
This article was originally published in PharmAsia News
Executive SummaryWhile China made progress overhauling the drug and device regulations this year, multinationals are worried about a few things the government has yet to tackle: defining what constitutes a "new chemical entity," assuring the confidentiality of data submitted for drug registration, and linking drug approvals to patent protection
You may also be interested in...
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).